Explore

Rapid Read Rapid Read
Study Reveals Flu Vaccine Prevents Up to 14 Cases Per 100 Children, Highlights Importance of Vaccination

Study Reveals Flu Vaccine Prevents Up to 14 Cases Per 100 Children, Highlights Importance of Vaccination

A study published in JAMA Pediatrics suggests that the childhood influenza vaccine can prevent between 9 and 14 cases of flu per 100 children vaccinated. Researchers at Harvard Medical School analyzed insurance claims for children aged two to five years over five flu seasons, excluding the 2020/2021 and 2021/2022 seasons due to COVID-19 confounding factors. The study found that vaccination rates were higher among children with autumn birthdays compared to those with summer birthdays, correlating with lower influenza diagnosis rates. The study coincides with discussions in the UK about the role of community pharmacies in delivering childhood vaccinations.
Trendline Trendline
Health Experts Highlight Risks and Uncertain Benefits of Alkaline Water Craze

Health Experts Highlight Risks and Uncertain Benefits of Alkaline Water Craze

Health Experts Highlight Risks and Uncertain Benefits of Alkaline Water Craze
Rapid Read Rapid Read
MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

Researchers at the Massachusetts Institute of Technology (MIT) have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The study, published in Science Advances, suggests that the adjuvant, known as Am80, can be delivered using lipid nanoparticles to stimulate immune cells to target the mucosal lining of the intestine. This approach aims to combine the safety of the injectable polio vaccine with the mucosal immunity typically provided by the oral polio vaccine, which some countries have stopped using due to a small risk of infection.
Rapid Read Rapid Read
MIT and Harvard Researchers Investigate Fever's Impact on Autism Symptoms

MIT and Harvard Researchers Investigate Fever's Impact on Autism Symptoms

Researchers from MIT and Harvard Medical School are exploring the phenomenon where autism symptoms appear to ease during a fever. This 'fever effect' has been observed by parents and caregivers, and the research team, supported by a $2.1 million grant from the Marcus Foundation, aims to understand the underlying biology. Neuroscientist Gloria Choi and immunologist Jun Huh have conducted a decade of research in mice, identifying an immune-signaling molecule, IL-17a, that seems to calm overactive brain circuits during infections. Their findings suggest that the improvement in symptoms is linked to this molecule rather than the fever itself. The team plans to create a biobank of blood and stool samples from volunteers to further investigate these markers in humans.
Rapid Read Rapid Read
Efforts to Develop Vaccine for Ebola Bundibugyo Strain Intensify

Efforts to Develop Vaccine for Ebola Bundibugyo Strain Intensify

Global vaccine non-profits are accelerating efforts to develop a vaccine for the Bundibugyo strain of Ebola, which is driving the current outbreak in the Democratic Republic of Congo and Uganda. The Coalition for Epidemic Preparedness Innovation (CEPI) and Gavi have committed over $100 million to fast-track research and development of vaccine candidates. CEPI is investing $62 million in three vaccine candidates, while Gavi is contributing $40 million to create a market for a successful vaccine. The urgency stems from the strain's rapid spread and the lack of approved vaccines or treatments for Bundibugyo.
Rapid Read Rapid Read
Cambridge Team Completes Phase 1 Trial of AI-Designed Universal Coronavirus Vaccine

Cambridge Team Completes Phase 1 Trial of AI-Designed Universal Coronavirus Vaccine

A research team from the University of Cambridge, in collaboration with DIOSynVax (DVX) Ltd, has successfully completed a Phase 1 human trial of an AI-designed universal Sarbeco coronavirus vaccine, known as pEVAC-PS. The trial, which was open-label and dose-escalation in nature, involved 39 healthy volunteers aged between 18 and 50. The vaccine, which is DNA-based and administered via a needle-free microfluidic jet system, was found to be safe and well tolerated. Participants developed immune responses to SARS-CoV-2, SARS, and related bat coronaviruses. The core antigen of the vaccine was designed using machine learning to create a 'super-antigen' targeting conserved features across the virus family. The study was conducted at the National Institute for Health and Care Research (NIHR) Clinical Research Facilities in Southampton and Cambridge.
Rapid Read Rapid Read
CEPI and Gavi Fund Development of Ebola Vaccine for Bundibugyo Strain Amid DRC Outbreak

CEPI and Gavi Fund Development of Ebola Vaccine for Bundibugyo Strain Amid DRC Outbreak

The Coalition for Epidemic Preparedness Innovation (CEPI) and Gavi, a global vaccine alliance, have committed over $100 million to fast-track the development of vaccines targeting the Bundibugyo strain of Ebola, which is currently driving a significant outbreak in the Democratic Republic of Congo (DRC). Three vaccine candidates are being developed by IAVI, the University of Oxford, and Moderna. IAVI's candidate, which uses a vesicular stomatitis virus to deliver immune instructions, is the most advanced in testing. Despite the funding, it will take months to determine the vaccines' efficacy and even longer for widespread use. The urgency of the situation is underscored by the outbreak's scale, which is one of the largest on record.
Rapid Read Rapid Read
Chitosan Nanoparticles Offer New Hope for Stable, Needle-Free Vaccines

Chitosan Nanoparticles Offer New Hope for Stable, Needle-Free Vaccines

A recent review in npj Vaccines highlights the potential of chitosan-based nanovaccines to enhance vaccine stability and delivery. Chitosan, a natural polymer, is used to create nanostructures that protect antigens and boost immune responses. These nanovaccines could reduce reliance on cold-chain storage and enable needle-free administration. Initial studies show promising safety profiles and immune responses, but human trials have been inconsistent. The review emphasizes the need for standardized chitosan materials to ensure reproducible production and clinical efficacy.
Rapid Read Rapid Read
AI-Designed Universal Coronavirus Vaccine Successfully Completes First Human Trial

AI-Designed Universal Coronavirus Vaccine Successfully Completes First Human Trial

A new universal coronavirus vaccine, developed using artificial intelligence, has successfully passed its first human clinical trial. Created by researchers at the University of Cambridge and DIOSynVax Ltd, the vaccine was tested on 39 healthy volunteers and found to be safe with no significant side effects. Unlike traditional vaccines, this AI-designed vaccine targets multiple members of the Sarbeco coronavirus family, including SARS-CoV-2 and related bat coronaviruses. The trial demonstrated that the vaccine could stimulate immune responses against these viruses, marking a significant step toward broader protection against future outbreaks.
Rapid Read Rapid Read
Cambridge Team Completes Phase 1 Trial of AI-Designed Universal Vaccine

Cambridge Team Completes Phase 1 Trial of AI-Designed Universal Vaccine

A team led by the University of Cambridge, in collaboration with DIOSynVax (DVX) Ltd, has successfully completed the first-in-human Phase 1 trial of an AI-designed universal Sarbeco coronavirus vaccine, known as pEVAC-PS. The trial, which was open-label and dose-escalation in nature, involved 39 healthy volunteers aged between 18 and 50. The vaccine, which is DNA-based and needle-free, was found to be safe and well-tolerated, eliciting immune responses to SARS-CoV-2, SARS, and related bat coronaviruses. The antigen used in the vaccine was designed using machine learning to target conserved features across the virus family, based on global viral surveillance data. Although the immunogenicity was described as 'modest' due to participants' prior COVID-19 exposure, the study marks a significant step in vaccine development.
Rapid Read Rapid Read
Study Shows Flu Vaccine Can Prevent Up to 14 Cases Per 100 Children, Highlighting Importance of Vaccination

Study Shows Flu Vaccine Can Prevent Up to 14 Cases Per 100 Children, Highlighting Importance of Vaccination

A study published in JAMA Pediatrics suggests that the childhood influenza vaccine can prevent between 9 and 14 cases of flu per 100 children vaccinated. Researchers at Harvard Medical School analyzed insurance claims for children aged two to five years over five flu seasons, excluding the 2020/2021 and 2021/2022 seasons due to COVID-19 confounding factors. The study found that vaccination rates for children with autumn birthdays were higher than those with summer birthdays, correlating with lower influenza diagnosis rates. The study coincides with discussions in the UK about the role of community pharmacies in delivering childhood vaccinations.
Rapid Read Rapid Read
MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

Researchers at the Massachusetts Institute of Technology have developed a new adjuvant that could enhance the mucosal immunity of the injectable polio vaccine. The injectable form of the polio vaccine is effective at preventing illness but does not block virus transmission as effectively as the oral version. The oral vaccine induces a mucosal immune response in the gastrointestinal tract, which is the primary site of virus exposure. However, due to a small risk of infection, several countries have stopped using the oral vaccine. The new adjuvant, known as Am80, is delivered with a lipid nanoparticle that releases it slowly, allowing for a sustained immune response. This approach aims to combine the safety of the injectable vaccine with the mucosal immunity benefits of the oral vaccine, potentially aiding in polio eradication efforts.